Literature DB >> 29948349

Recognition and control of hypertension, diabetes, and dyslipidemia in patients with systemic lupus erythematosus.

Luísa Lima Castro1, Cristina Costa Duarte Lanna2, Antônio Luiz Pinho Ribeiro2, Rosa Weiss Telles2.   

Abstract

Systemic lupus erythematosus (SLE) patients have a high risk for cardiovascular events, but few studies have evaluated the recognition and none have evaluated the control of cardiovascular risk factors (RF) in SLE patients. The study aims to describe the recognition and control frequencies of systemic arterial hypertension (SAH), dyslipidemia, and diabetes mellitus (DM) in SLE patients. Of the female patients with SLE, 137 answered a questionnaire focused on general knowledge of the RF for coronary artery disease (CAD) and on recognition of the risk factors that they possess. The patient's information collected on a structured medical record was reviewed to evaluate the RF control. The mean age was 29.1 (9.6) years. Seventy patients had SAH; 85.7% recognized their condition and 71.4% had desirable blood pressure (BP) control (< 140 × 90 mmHg). From a group of 63 patients with dyslipidemia, 68.3% recognized that they had dyslipidemia and 69.8% had desirable LDL-cholesterol (< 130 mg/dL). Sixteen patients had DM; 87.5% admitted being diabetic and 50.0% had desirable glycemic control (HbA1C < 7%). Most patients were aware of presenting SAH, DM, or dyslipidemia, and the recognition frequency was higher in comparison to general population. The SAH and dyslipidemia control frequencies were higher than that described for the general population.

Entities:  

Keywords:  Diabetes; Dyslipidemia; Hypertension; Risk factors for coronary artery disease; Systemic lupus erythematosus

Mesh:

Year:  2018        PMID: 29948349     DOI: 10.1007/s10067-018-4169-0

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  29 in total

1.  [VI Brazilian Guidelines on Hypertension].

Authors: 
Journal:  Arq Bras Cardiol       Date:  2010-07       Impact factor: 2.000

2.  [V Brazilian Guidelines on Dyslipidemias and Prevention of Atherosclerosis].

Authors:  H T Xavier; M C Izar; J R Faria Neto; M H Assad; V Z Rocha; A C Sposito; F A Fonseca; J E dos Santos; R D Santos; M C Bertolami; A A Faludi; T L R Martinez; J Diament; A Guimarães; N A Forti; E Moriguchi; A C P Chagas; O R Coelho; J A F Ramires
Journal:  Arq Bras Cardiol       Date:  2013-10       Impact factor: 2.000

3.  Modification of hypertension and hypercholesterolaemia in patients with systemic lupus erythematosus: a quality improvement study.

Authors:  M B Urowitz; D D Gladman; D Ibanez; Y Berliner
Journal:  Ann Rheum Dis       Date:  2006-01       Impact factor: 19.103

4.  Cardiac risk factor awareness and management in patients with systemic lupus erythematosus.

Authors:  Karen H Costenbader; Elizabeth Wright; Matthew H Liang; Elizabeth W Karlson
Journal:  Arthritis Rheum       Date:  2004-12-15

5.  Trends in prevalence, awareness, treatment and control of hypertension in urban communities in Chile.

Authors:  Eduardo Fasce; Ivone Campos; Pilar Ibáñez; Maritza Flores; Hernán Zárate; Oscar Román; Fabrizio Fasce
Journal:  J Hypertens       Date:  2007-09       Impact factor: 4.844

6.  Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome.

Authors:  Sònia Jiménez; M Angels García-Criado; Dolors Tàssies; Joan Carles Reverter; Ricard Cervera; M Rosa Gilabert; Daniel Zambón; Emilio Ros; Concepció Bru; Josep Font
Journal:  Rheumatology (Oxford)       Date:  2005-03-09       Impact factor: 7.580

7.  Trends in prevalence, awareness, management, and control of hypertension among United States adults, 1999 to 2010.

Authors:  Fangjian Guo; Di He; Wei Zhang; R Grace Walton
Journal:  J Am Coll Cardiol       Date:  2012-07-11       Impact factor: 24.094

Review 8.  Trends in prevalence of hypertension in Brazil: a systematic review with meta-analysis.

Authors:  Rafael V Picon; Flávio D Fuchs; Leila B Moreira; Glaube Riegel; Sandra C Fuchs
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

9.  Level of unawareness and management of diabetes, hypertension, and dyslipidemia among adults in Luxembourg: findings from ORISCAV-LUX study.

Authors:  Ala'a Alkerwi; Sybil Pagny; Marie-Lise Lair; Charles Delagardelle; Jean Beissel
Journal:  PLoS One       Date:  2013-03-04       Impact factor: 3.240

10.  Dyslipidemia awareness, treatment, control and influence factors among adults in the Jilin province in China: a cross-sectional study.

Authors:  Huan He; Ya-qin Yu; Yong Li; Chang-gui Kou; Bo Li; Yu-chun Tao; Qing Zhen; Chang Wang; Joseph Sam Kanu; Xu-feng Huang; Mei Han; Ya-wen Liu
Journal:  Lipids Health Dis       Date:  2014-08-03       Impact factor: 3.876

View more
  1 in total

Review 1.  Lipid Metabolism: Immune Regulation and Therapeutic Prospectives in Systemic Lupus Erythematosus.

Authors:  Wei Sun; Pengchong Li; Jianping Cai; Jie Ma; Xuan Zhang; Yong Song; Yudong Liu
Journal:  Front Immunol       Date:  2022-03-18       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.